Key Takeaways
- Imatinib works by blocking the abnormal bcr-abl protein produced by the Philadelphia chromosome, which stops cancer cells from growing and causes them to die.
- Imatinib can increase levels of other medications that are broken down by your liver, so your doctor may need to adjust doses of other drugs you take.
- Certain medications can lower imatinib levels in your body, while others can raise them, so always tell your doctor about all the drugs and supplements you use.
- If you need blood thinners, use heparin instead of warfarin while taking imatinib.
- Do not breastfeed while taking imatinib, as it may harm your baby.
What Is Imatinib Mesylate?
Imatinib Mesylate is a protein-tyrosine kinase inhibitor specifically designed to target the bcr-abl tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myelogenous leukemia (CML). As an antineoplastic agent, Imatinib works by inhibiting the abnormal protein that drives cancer cell proliferation, thereby inducing apoptosis and halting disease progression.
This targeted therapy represents a paradigm shift in oncology treatment, moving from traditional chemotherapy to precision medicine that specifically attacks cancer cells while minimizing damage to healthy tissue. The medication’s mechanism of action involves competitive inhibition at the ATP-binding site of the bcr-abl tyrosine kinase, effectively blocking the signal transduction pathways that lead to uncontrolled cell growth.
Regulatory Approvals and Quality Standards
Imatinib Mesylate has received regulatory approval from multiple international health authorities, demonstrating its safety and efficacy profile across diverse patient populations. The medication has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, accelerated phase, and blast crisis. The European Medicines Agency (EMA) has similarly approved Imatinib for these indications, ensuring access for patients across European Union member states.
This content is based on official prescribing information and product monographs approved by regulatory authorities. Healthcare professionals should consult the complete prescribing information for detailed dosing guidelines, contraindications, and safety data specific to their jurisdiction.
Available Formulations and Manufacturers
Available as Imaxen and Imacent, this medication serves as a proven alternative to the originator brand Glivec, offering the same therapeutic benefits for patients with Philadelphia chromosome-positive CML. The 400mg Imatinib dosage represents a cornerstone treatment option for both newly diagnosed patients and those requiring second-line therapy in blast phase.
Manufactured by GMP-certified facilities including Everest Pharmaceuticals Ltd. and Incepta Pharmaceuticals Ltd., Imatinib Mesylate tablets are produced under stringent quality control standards that meet or exceed international pharmaceutical manufacturing guidelines. These manufacturers maintain compliance with Good Manufacturing Practice (GMP) standards as required by WHO, FDA, and other regulatory bodies.
The medication is available in 100 mg and 400 mg tablet formulations to accommodate different dosing requirements based on patient age, weight, disease phase, and treatment response. This dosing flexibility allows healthcare providers to tailor treatment regimens to individual patient needs while maintaining optimal therapeutic outcomes.
Clinical Applications and Treatment Guidelines
Imatinib Mesylate is recognized for its efficacy in first-line treatment of newly diagnosed Ph+ CML in both adults and pediatric patients in chronic phase. Clinical studies have demonstrated that Imatinib achieves high rates of complete hematologic response, major cytogenetic response, and complete cytogenetic response, significantly improving long-term survival outcomes compared to historical treatment options.
Beyond chronic phase CML, Imatinib has established efficacy in treating accelerated phase and blast crisis CML, providing therapeutic options for patients with advanced disease. The medication has also received approvals for additional oncologic indications including Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit (CD117) positive gastrointestinal stromal tumors (GIST).
Quality Assurance and Supply Chain Integrity
As a specialist oncology medicine supplier, we maintain rigorous quality assurance protocols throughout our supply chain to ensure product integrity from manufacturer to end user. All Imatinib products in our portfolio are sourced directly from approved manufacturers, stored under controlled conditions as specified in product monographs, and distributed through validated cold chain systems where required.
Our quality management system includes:
- Verification of manufacturer GMP certification and regulatory approvals
- Batch-specific certificate of analysis review
- Temperature-controlled storage and transportation
- Serialization and track-and-trace capabilities for anti-counterfeiting
- Regular stability testing to confirm product integrity throughout shelf life
Resources for Healthcare Professionals
Healthcare providers prescribing Imatinib should be aware of important safety considerations including potential drug interactions, contraindications in pregnancy, and the need for regular monitoring of complete blood counts and liver function tests. Dose modifications may be required based on patient response, tolerability, and concurrent medications.
Therapeutic drug monitoring may be beneficial in certain clinical situations, as Imatinib plasma concentrations have been correlated with treatment response. Healthcare professionals should consult current clinical guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) and the European LeukemiaNet (ELN) for the most up-to-date treatment recommendations.
Supply and Distribution Information
For healthcare providers, hospital pharmacies, and pharmaceutical distributors seeking reliable access to this essential cancer therapy, we offer comprehensive supply chain solutions tailored to your specific requirements. Our global distribution network ensures consistent availability of quality-assured Imatinib products with full regulatory documentation and cold chain integrity.
Contact us for:
- Current pricing and volume discounts
- Product availability and lead times
- Regulatory documentation packages
- Technical product information
- Custom supply agreements for institutional buyers
Our team of pharmaceutical specialists provides technical support to ensure appropriate product selection, storage, and handling throughout the distribution chain.
Important Safety Information
This information is intended for healthcare professionals and pharmaceutical trade partners only. Imatinib Mesylate is a prescription medication that should only be used under the supervision of a qualified healthcare provider experienced in the treatment of oncologic disorders. Patients should not adjust dosing or discontinue therapy without consulting their treating physician. For complete safety information, contraindications, warnings, and precautions, please consult the full prescribing information approved by your local regulatory authority.
References and Further Information
This article is based on information from official regulatory sources, manufacturer prescribing information, and peer-reviewed medical literature. Healthcare professionals should always consult the most current prescribing information and clinical guidelines when making treatment decisions.
Key Regulatory Sources:
- U.S. Food and Drug Administration (FDA) – Center for Drug Evaluation and Research
- European Medicines Agency (EMA) – Product Information Database
- WHO Essential Medicines List and Technical Reports
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
- Manufacturer Product Monographs – Everest Pharmaceuticals Ltd. and Incepta Pharmaceuticals Ltd.
Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. Healthcare professionals should exercise their own clinical judgment and consult official prescribing information before prescribing or dispensing any medication. Oncosolution is a pharmaceutical supplier and distributor; this content does not replace consultation with qualified healthcare providers or official regulatory guidance.
Access This Medicine Through oncosolution
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
[Contact form / email button]
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.